
Helena A. Yu, MD, and Joshua K. Sabari, MD, look to the future of frontline treatment in EGFR exon 20–mutated non–small cell lung cancer.

Helena A. Yu, MD, and Joshua K. Sabari, MD, look to the future of frontline treatment in EGFR exon 20–mutated non–small cell lung cancer.

Lung cancer experts discuss how these real-world data comparing amivantamab with alternative therapies may impact their clinical practice.

Joshua K. Sabari, MD, and Helena A. Yu, MD, discuss real-world data comparing amivantamab with other therapies in EGFR exon 20–mutated non–small cell lung cancer.

A comprehensive overview of the methods utilized in a real-world analysis of amivantamab vs other therapies in patients with EGFR exon 20–mutated NSCLC.

Expert oncologists review the CHRYSALIS trial, which resulted in the approval of amivantamab in the second line for patients with locally advanced or metastatic NSCLC with exon 20 mutations.

Experts on non–small cell lung cancer discuss treatment options for patients with EGFR exon 20 mutations in the first line and beyond.

Joshua K. Sabari, MD, and Helena A. Yu, MD, experts on non–small cell lung cancer, give an overview of EGFR exon 20 insertion mutations.